sábado, 14 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 3, 2026

Crypto News: AlphaPepe Stage 10 Nearly Sold Out Prior Big Price Rise As XRP Eyes $5 Breakout

View original at globenewswire.com
Crypto News: AlphaPepe Stage 10 Nearly Sold Out Prior Big Price Rise As XRP Eyes $5 Breakout MONACO, April 03, 2026 (GLOBE NEWSWIRE) -- AlphaPepe Stage 10 is nearly sold out and the next stage brings a significant price increase…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Five specific catalysts could drive the XRP breakout: a potential BlackRock XRP ETF filing, Japan's RLUSD launch through licensed banks, real-world asset tokenization via Archax on the XRP Ledger, Federal Reserve rate cuts pushing capital into risk assets, and supply tightening from exchange outflows

    60% confidence

  • XRP posted its worst quarter in eight years, dropping 27.1% in Q1 2026

    60% confidence

  • XRP reaching $5 sits at the top of analyst forecasts for 2026 with a consensus range closer to $3 to $4

    60% confidence

  • The path to $5 requires the CLARITY Act to pass the Senate, which would classify XRP as a digital commodity under federal law, and ETF inflows to reach approximately $5 billion

    60% confidence

Data points we hold from this source

XRP · stock price1.33 USD
XRP · market cap29000000000.0 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Crypto News: AlphaPepe Stage 10 Nearly Sold Out Prior Big Price Rise As XRP Eyes $5 Breakout — Source | Via News | pt.VIA.NEWS